Sara Pérez Jaume
Investigador post-doc
Research group
Professional network profiles
Last Publications
- Ana Carolina Izurieta Pacheco, Noyd DH, Challinor J, Rossell N, Olarte-Sierra MF, Blanco DB, Zubieta M, George NB, Pérez-Jaume S, Felip-Badia A, Trigoso V, Loggetto P, Gonzalez V, Frias C, Rincon S, Ortiz R, de Aparicio SF and Ponce LV Childhood Cancer Survivors in Latin America: Insights Into Health Outcomes and Information Needs. PEDIATRIC BLOOD & CANCER . 72(9): .
- Esther Martínez García, López de San Roman Fernández C, Nishishinya Aquino MB, Pérez-Jaume S, Fernández-Jané C, Cruz-Martínez O and Morales-La Madrid A Patient Acceptability of the First Integrative Pediatric Oncology Unit in Spain-The Pediatric Cancer Center Barcelona Experience: A Retrospective Study Cancers . 17(2): .
- Pérez-Jaume S and Carrasco, Josep L. Comparison of optimum threshold estimators in the binormal setting JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION . : .
Projects
- Project name:
- Nuevas técnicas para la caracterización molecular completa y la mejora del seguimiento de la enfermedad mínima residual en leucemia aguda pediátrica
- Leader
- Mireia Camós Guijosa, Nerea Vega García
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00213
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Desarrollo de clasificadores epigenéticos para el Cáncer Pediátrico (ECPC)
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00519
- Starting - finishing date:
- 2021 - 2025
- Project name:
- Método para la clasificación en subgrupos moleculares de pacientes con Meduloblastoma
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI17/00353
- Starting - finishing date:
- 2018 - 2022
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
More activities
-
Defensa tesi doctoral: Sara Pérez Jaume
Auditorio J Plaza del Hospital Sant Joan de Déu y online